Gastrointestinal sequelae among COVID-19 patients after discharge and their predictors

Samanta, Jayanta; Singh, Satbir; Kumar, Sanjay; Sharma, Megha; Kochhar, Rakesh

doi:10.1016/j.dld.2022.02.002

Cited by 3 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have reported that GI sequelae after COVID-19 infection (mostly diarrhea, loss of appetite, nausea, abdominal discomfort, and acid reflux) are observed with high variability, ranging from 16% to 44% at 3 months from discharge, particularly in patients initially presenting with severe disease. 40 , 41 However, such estimations are hindered by heterogeneous definition of symptoms and manifestations, as well as variable methods and duration of follow-up. Given the known high prevalence of post-infectious generic GI symptoms, 42 prospective controlled protocols may be necessary to elucidate the severity and duration of such sequelae and their relevance to patients.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal manifestations of SARS-CoV-2 infection in an Italian population of hospitalized patients

Milano

Efthymakis

D’Ardes

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters the cells via angiotensin-converting enzyme 2 receptor; therefore, tissues expressing this receptor are potential targets for infection. Although many studies have observed gastrointestinal (GI) symptoms in coronavirus disease 2019 (COVID-19) patients, prevalence and clinical impact are still uncertain due to the heterogeneity of reports and obstacles to generalization. Methods: In this cross-sectional study, we included symptomatic patients requiring hospital admission, with a confirmed diagnosis of COVID-19 by nasopharyngeal polymerase chain reaction test, between 18 March and 30 May 2020. Demographic data, symptoms at onset, vital signs, and laboratory tests at admission were recorded. Results: In all, 300 patients were included (57%M, 43%F). GI symptoms were mainly diarrhea (13%), anorexia (4.3%), vomiting (3%), and abdominal pain (2.3%). Overall, males were younger (68 years versus 76 years; p = 0.01); patients with GI manifestations at disease onset required significantly faster hospital admission and showed larger GI complication rates. GI symptoms were associated with abnormal high aspartate aminotransferase and alanine aminotransferase serum titers, especially in male patients. Conclusion: Our study on an Italian population during the outbreak of the COVID-19 pandemic shows that GI symptoms are part of the spectrum of the SARS-CoV-2 infection and could be the only manifestations at disease onset. Although patients with GI symptoms were associated with faster hospital admission and liver involvement, prognosis was not affected.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastrointestinal manifestations of SARS-CoV-2 infection in an Italian population of hospitalized patients

Milano

Efthymakis

D’Ardes

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Проспективное наблюдение 203 пациентов перенесших COVID-19 показало, что через 3 месяца после выписки у 15,7% имели желудочнок ишечные п роявлени я (боль/дискомфорт в животе, запор, жидкий стул, тошнота и рвота и стойкое снижение аппетита). При многомерном регрессионном анализе тяжелая инфекция COVID-19, потребность в дополнительном кислороде, пребывание в отделении интенсивной терапии и введение стероидов во время госпитализации были значимыми предикторами последующих желудочно-кишечных симптомов с поправкой на возраст, пол и профиль симптомов во время госпитализации [89].…”

Section: распространенность поражений органов пищеварения при постков...unclassified

“…Указанные симптомы (дискомфорт и боль в эпигастрии, чувство раннего насыщения, снижение или отсутствие аппетита, тошнота, рвота) установлены у пациентов с постковидным синдромом во многих исследованиях [89,91,92,108].…”

Section: комментарииunclassified

“…Через 3 месяца после выписки из стационара 15,7% пациентов имели кишечные проявления (запор / диарея, дискомфорт / боль в животе, снижение аппетита) [89].…”

Section: гастроэнтерологический постковидный синдром C поражением киш...unclassified

See 1 more Smart Citation

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

Гриневич

Лазебник

Kravchuk

et al. 2023

jour

View full text Add to dashboard Cite

Summary Post- COVID syndrome refers to the long-term consequences of a new coronavirus infection COVID-19, which includes a set of symptoms that develop or persist after COVID-19. Symptoms of gastrointestinal disorders in post- COVID syndrome, due to chronic infl ammation, the consequences of organ damage, prolonged hospitalization, social isolation, and other causes, can be persistent and require a multidisciplinary approach. The presented clinical practice guidelines consider the main preventive and therapeutic and diagnostic approaches to the management of patients with gastroenterological manifestations of postCOVID syndrome. The Guidelines were approved by the 17th National Congress of Internal Medicine and the 25th Congress of Gastroenterological Scientifi c Society of Russia.

show abstract

“…Thus, there is an urgent need for measures to prevent re-infection ( Boufidou et al, 2023 ). Due to the high contagiosity of COVID-19, increased risk of mortality rate from critical illness ( Jia and Gong, 2021 ), and the emergence of associated sequelae ( Samanta et al, 2022 ; Stefanou et al, 2022 ), preventative measures for recurrent, new, or suspected COVID-19 cases are warranted.…”

Section: Introductionmentioning

confidence: 99%

An updated meta-analysis of Chinese herbal medicine for the prevention of COVID-19 based on Western-Eastern medicine

Hu,

Luo,

Zhu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background and aims: Chinese herbal medicine (CHM) was used to prevent and treat coronavirus disease 2019 (COVID-19) in clinical practices. Many studies have demonstrated that the combination of CHM and Western medicine can be more effective in treating COVID-19 compared to Western medicine alone. However, evidence-based studies on the prevention in undiagnosed or suspected cases remain scarce. This systematic review and meta-analysis aimed to investigate the effectiveness of CHM in preventing recurrent, new, or suspected COVID-19 diseases.Methods: We conducted a comprehensive search using ten databases including articles published between December 2019 and September 2023. This search aimed to identify studies investigating the use of CHM to prevent COVID-19. Heterogeneity was assessed by a random-effects model. The relative risk (RR) and mean differences were calculated using 95% confidence intervals (CI). The modified Jadad Scale and the Newcastle-Ottawa Scale (NOS) were employed to evaluate the quality of randomized controlled trials and cohort studies, respectively.Results: Seventeen studies with a total of 47,351 patients were included. Results revealed that CHM significantly reduced the incidence of COVID-19 (RR = 0.24, 95% CI = 0.11–0.53, p = 0.0004), influenza (RR = 0.37, 95% CI = 0.18–0.76, p = 0.007), and severe pneumonia exacerbation rate (RR = 0.17, 95% CI = 0.05–0.64, p = 0.009) compared to non-treatment or conventional control group. Evidence evaluation indicated moderate quality evidence for COVID-19 incidence and serum complement components C3 and C4 in randomized controlled trials. For the incidence of influenza and severe pneumonia in RCTs as well as the ratio of CD4+/CD8+ lymphocytes, the evidence quality was low. The remaining outcomes including the disappearance rate of symptoms and adverse reactions were deemed to be of very low quality.Conclusion: CHM presents a promising therapeutic option for the prevention of COVID-19. However, additional high-quality clinical trials are needed to further strengthen evidential integrity.

show abstract

Gastrointestinal sequelae among COVID-19 patients after discharge and their predictors

Cited by 3 publications

References 7 publications

Gastrointestinal manifestations of SARS-CoV-2 infection in an Italian population of hospitalized patients

Gastrointestinal manifestations of SARS-CoV-2 infection in an Italian population of hospitalized patients

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

An updated meta-analysis of Chinese herbal medicine for the prevention of COVID-19 based on Western-Eastern medicine

Contact Info

Product

Resources

About